Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY25 results · Apr–Jun 2024
Aarti Drugs reported revenue from operations of ₹555.34 crore (down 16.0% from Q1 FY24) and net profit of ₹33.27 crore (down 30.6% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 555.34 | 661.11 | −16.0% | 619.99 | −10.4% |
| Other income | 1.11 | 0.60 | +85.0% | 1.08 | +2.8% |
| Total income | 556.45 | 661.71 | −15.9% | 621.07 | −10.4% |
| Profit before tax | 43.98 | 63.53 | −30.8% | 64.18 | −31.5% |
| Net profit for the period | 33.27 | 47.97 | −30.6% | 47.31 | −29.7% |
| Attributable to shareholders of the company | 33.24 | — | — | 47.37 | −29.8% |
| EPS, basic (₹) | 3.62 | 5.18 | −30.1% | 5.15 | −29.7% |
| Net margin (%) | 6.0 | 7.3 | 7.6 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 492.96 | 591.63 | −16.7% | 559.53 | −11.9% |
| Other income | 0.11 | 0.65 | −83.1% | 1.11 | −90.1% |
| Total income | 493.07 | 592.28 | −16.8% | 560.64 | −12.1% |
| Profit before tax | 35.16 | 53.04 | −33.7% | 49.74 | −29.3% |
| Net profit for the period | 26.91 | 39.54 | −31.9% | 36.14 | −25.5% |
| EPS, basic (₹) | 2.93 | 4.27 | −31.4% | 3.93 | −25.4% |
| Net margin (%) | 5.5 | 6.7 | 6.5 |
Consolidated
- Filed with BSE
- 29 Jul 2024, 18:00 IST
- Board meeting
- 26 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 29 Jul 2024, 18:00 IST
- Board meeting
- 26 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Audited
- Source
- XBRL filing on BSE